Neurobiology of Aging
Volume 28, Issue 4 , Pages 568-578 , April 2007

Altered expression of vesicular glutamate transporters VGLUT1 and VGLUT2 in Parkinson disease

  • Alireza Kashani

      Affiliations

    • INSERM U513, Faculté de Médecine, Université Paris XII, 8 rue du Général Sarrail, 94010 Créteil Cedex, France
    • ,
  • Catalina Betancur

      Affiliations

    • INSERM U513, Faculté de Médecine, Université Paris XII, 8 rue du Général Sarrail, 94010 Créteil Cedex, France
    • ,
  • Bruno Giros

      Affiliations

    • INSERM U513, Faculté de Médecine, Université Paris XII, 8 rue du Général Sarrail, 94010 Créteil Cedex, France
    • ,
  • Etienne Hirsch

      Affiliations

    • INSERM U679, CHU Pitié-Salpêtrière, 47 boulevard de l’Hôpital, 75013 Paris, France
    • ,
  • Salah El Mestikawy

      Affiliations

    • INSERM U513, Faculté de Médecine, Université Paris XII, 8 rue du Général Sarrail, 94010 Créteil Cedex, France
    • Corresponding Author InformationCorresponding author. Tel.: +33 1 49 81 36 06; fax: +33 1 49 81 36 85.

Received 5 October 2005 ,Revised 3 February 2006 ,Accepted 14 February 2006.

References 

  1. Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sorensen P. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol. 2003;60:387–392
  2. Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord. 2001;16:448–458
  3. Albin RL, Young AB, Penney JB. The functional anatomy of basal ganglia disorders. Trends Neurosci. 1989;12:366–375
  4. Anglade P, Mouatt-Prigent A, Agid Y, Hirsch E. Synaptic plasticity in the caudate nucleus of patients with Parkinson's disease. Neurodegeneration. 1996;5:121–128
  5. Bellocchio EE, Reimer RJ, Fremeau RT, Edwards RH. Uptake of glutamate into synaptic vesicles by an inorganic phosphate transporter. Science. 2000;289:957–960
  6. Bellocchio EE, Hu H, Pohorille A, Chan J, Pickel VM, Edwards RH. The localization of the brain-specific inorganic phosphate transporter suggests a specific presynaptic role in glutamatergic transmission. J Neurosci. 1998;18:8648–8659
  7. Calabresi P, Mercuri NB, Sancesario G, Bernardi G. Electrophysiology of dopamine-denervated striatal neurons. Implications for Parkinson's disease. Brain. 1993;116:433–452
  8. Calabresi P, Pisani A, Mercuri NB, Bernardi G. The corticostriatal projection: from synaptic plasticity to dysfunctions of the basal ganglia. Trends Neurosci. 1996;19:19–24
  9. Carlsson M, Carlsson A. The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine-depleted mice. J Neural Transm. 1989;75:221–226
  10. Centonze D, Calabresi P, Giacomini P, Bernardi G. Neurophysiology of Parkinson's disease: from basic research to clinical correlates. Clin Neurophysiol. 1999;110:2006–2013
  11. Cummings JL. Intellectual impairment in Parkinson's disease: clinical, pathologic, and biochemical correlates. J Geriatr Psychiatry Neurol. 1988;1:24–36
  12. Daniels RW, Collins CA, Gelfand MV, Dant J, Brooks ES, Krantz DE, et al. Increased expression of the drosophila vesicular glutamate transporter leads to excess glutamate release and a compensatory decrease in quantal content. J Neurosci. 2004;24:10466–10474
  13. Defebvre L, Lecouffe P, Destee A, Houdart P, Steinling M. Tomographic measurements of regional cerebral blood flow in progressive supranuclear palsy and Parkinson's disease. Acta Neurol Scand. 1995;92:235–241
  14. DeLong MR. Primate models of movement disorders of basal ganglia origin. Trends Neurosci. 1990;13:281–285
  15. Drouot X, Oshino S, Jarraya B, Besret L, Kishima H, Remy P, et al. Functional recovery in a primate model of Parkinson's disease following motor cortex stimulation. Neuron. 2004;44:769–778
  16. Dunah AW, Wang Y, Yasuda RP, Kameyama K, Huganir RL, Wolfe BB, et al. Alterations in subunit expression, composition, and phosphorylation of striatal N-methyl-d-aspartate glutamate receptors in a rat 6-hydroxydopamine model of Parkinson's disease. Mol Pharmacol. 2000;57:342–352
  17. Eberling JL, Richardson BC, Reed BR, Wolfe N, Jagust WJ. Cortical glucose metabolism in Parkinson's disease without dementia. Neurobiol Aging. 1994;15:329–335
  18. Eidelberg D, Moeller JR, Dhawan V, Spetsieris P, Takikawa S, Ishikawa T, et al. The metabolic topography of parkinsonism. J Cereb Blood Flow Metab. 1994;14:783–801
  19. Emre M. What causes mental dysfunction in Parkinson's disease?. Mov Disord. 2003;18(Suppl. 6):S63–S71
  20. Engber TM, Papa SM, Boldry RC, Chase TN. NMDA receptor blockade reverses motor response alterations induced by levodopa. Neuroreport. 1994;5:2586–2588
  21. Fremeau RT, Voglmaier S, Seal RP, Edwards RH. VGLUTs define subsets of excitatory neurons and suggest novel roles for glutamate. Trends Neurosci. 2004;27:98–103
  22. Fremeau RT, Kam K, Qureshi T, Johnson J, Copenhagen DR, Storm-Mathisen J, et al. Vesicular glutamate transporters 1 and 2 target to functionally distinct synaptic release sites. Science. 2004;304:1815–1819
  23. Fremeau RT, Troyer MD, Pahner I, Nygaard GO, Tran CH, Reimer RJ, et al. The expression of vesicular glutamate transporters defines two classes of excitatory synapse. Neuron. 2001;31:247–260
  24. Girault JA, Raisman-Vozari R, Agid Y, Greengard P. Striatal phosphoproteins in Parkinson disease and progressive supranuclear palsy. Proc Natl Acad Sci USA. 1989;86:2493–2497
  25. Gras C, Herzog E, Bellenchi GC, Bernard V, Ravassard P, Pohl M, et al. A third vesicular glutamate transporter expressed by cholinergic and serotoninergic neurons. J Neurosci. 2002;22:5442–5451
  26. Henderson JM, Carpenter K, Cartwright H, Halliday GM. Loss of thalamic intralaminar nuclei in progressive supranuclear palsy and Parkinson's disease: clinical and therapeutic implications. Brain. 2000;123:1410–1421
  27. Henderson JM, Carpenter K, Cartwright H, Halliday GM. Degeneration of the centre median-parafascicular complex in Parkinson's disease. Ann Neurol. 2000;47:345–352
  28. Herzog E, Gilchrist J, Gras C, Muzerelle A, Ravassard P, Giros B, et al. Localization of VGLUT3, the vesicular glutamate transporter type 3, in the rat brain. Neuroscience. 2004;123:983–1002
  29. Herzog E, Bellenchi GC, Gras C, Bernard V, Ravassard P, Bedet C, et al. The existence of a second vesicular glutamate transporter specifies subpopulations of glutamatergic neurons. J Neurosci. 2001;21:RC181
  30. Hirsch EC, Perier C, Orieux G, Francois C, Feger J, Yelnik J, et al. Metabolic effects of nigrostriatal denervation in basal ganglia. Trends Neurosci. 2000;23:S78–S85
  31. Hu MT, Taylor-Robinson SD, Chaudhuri KR, Bell JD, Labbe C, Cunningham VJ, et al. Cortical dysfunction in non-demented Parkinson's disease patients: a combined (31)P-MRS and (18)FDG-PET study. Brain. 2000;123:340–352
  32. Imon Y, Matsuda H, Ogawa M, Kogure D, Sunohara N. SPECT image analysis using statistical parametric mapping in patients with Parkinson's disease. J Nucl Med. 1999;40:1583–1589
  33. Kaneko T, Fujiyama F. Complementary distribution of vesicular glutamate transporters in the central nervous system. Neurosci Res. 2002;42:243–250
  34. Kaneko T, Fujiyama F, Hioki H. Immunohistochemical localization of candidates for vesicular glutamate transporters in the rat brain. J Comp Neurol. 2002;444:39–62
  35. Klockgether T. Parkinson's disease: clinical aspects. Cell Tissue Res. 2004;318:115–120
  36. Klockgether T, Turski L. NMDA antagonists potentiate antiparkinsonian actions of l-Dopa in monoamine-depleted rats. Ann Neurol. 1990;28:539–546
  37. Lange KW, Kornhuber J, Riederer P. Dopamine/glutamate interactions in Parkinson's disease. Neurosci Biobehav Rev. 1997;21:393–400
  38. Lees AJ, Smith E. Cognitive deficits in the early stages of Parkinson's disease. Brain. 1983;106:257–270
  39. Lindefors N, Ungerstedt U. Bilateral regulation of glutamate tissue and extracellular levels in caudate-putamen by midbrain dopamine neurons. Neurosci Lett. 1990;115:248–252
  40. Loschmann PA, Lange KW, Kunow M, Rettig KJ, Jahnig P, Honore T, et al. Synergism of the AMPA-antagonist NBQX and the NMDA-antagonist CPP with l-Dopa in models of Parkinson's disease. J Neural Transm Park Dis Dement Sect. 1991;3:203–213
  41. Martin-Ruiz CM, Piggott M, Gotti C, Lindstrom J, Mendelow AD, Siddique MS, et al. Alpha and beta nicotinic acetylcholine receptors subunits and synaptophysin in putamen from Parkinson's disease. Neuropharmacology. 2000;39:2830–2839
  42. Meshul CK, Cogen JP, Cheng HW, Moore C, Krentz L, McNeill TH. Alterations in rat striatal glutamate synapses following a lesion of the cortico- and/or nigrostriatal pathway. Exp Neurol. 2000;165:191–206
  43. Ni B, Wu X, Yan GM, Wang J, Paul SM. Regional expression and cellular localization of the Na(+)-dependent inorganic phosphate cotransporter of rat brain. J Neurosci. 1995;15:5789–5799
  44. Nieoullon A. Dopamine and the regulation of cognition and attention. Prog Neurobiol. 2002;67:53–83
  45. Orieux G, Francois C, Feger J, Yelnik J, Vila M, Ruberg M, et al. Metabolic activity of excitatory parafascicular and pedunculopontine inputs to the subthalamic nucleus in a rat model of Parkinson's disease. Neuroscience. 2000;97:79–88
  46. Owen AM, James M, Leigh PN, Summers BA, Marsden CD, Quinn NP, et al. Fronto-striatal cognitive deficits at different stages of Parkinson's disease. Brain. 1992;115(Pt 6):1727–1751
  47. Papa SM, Chase TN. Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys. Ann Neurol. 1996;39:574–578
  48. Sadikot AF, Parent A, Francois C. The centre median and parafascicular thalamic nuclei project respectively to the sensorimotor and associative-limbic striatal territories in the squirrel monkey. Brain Res. 1990;510:161–165
  49. Sidibe M, Smith Y. Thalamic inputs to striatal interneurons in monkeys: synaptic organization and co-localization of calcium binding proteins. Neuroscience. 1999;89:1189–1208
  50. Smith AD, Bolam JP. The neural network of the basal ganglia as revealed by the study of synaptic connections of identified neurones. Trends Neurosci. 1990;13:259–265
  51. Smith Y, Raju DV, Pare JF, Sidibe M. The thalamostriatal system: a highly specific network of the basal ganglia circuitry. Trends Neurosci. 2004;27:520–527
  52. Takamori S, Rhee JS, Rosenmund C, Jahn R. Identification of a vesicular glutamate transporter that defines a glutamatergic phenotype in neurons. Nature. 2000;407:189–194
  53. Takamori S, Rhee JS, Rosenmund C, Jahn R. Identification of differentiation-associated brain-specific phosphate transporter as a second vesicular glutamate transporter (VGLUT2). J Neurosci. 2001;21:RC182
  54. Varoqui H, Schafer MK, Zhu H, Weihe E, Erickson JD. Identification of the differentiation-associated Na+/PI transporter as a novel vesicular glutamate transporter expressed in a distinct set of glutamatergic synapses. J Neurosci. 2002;22:142–155
  55. Wilson NR, Kang J, Hueske EV, Leung T, Varoqui H, Murnick JG, et al. Presynaptic regulation of quantal size by the vesicular glutamate transporter VGLUT1. J Neurosci. 2005;25:6221–6234
  56. Wojcik SM, Rhee JS, Herzog E, Sigler A, Jahn R, Takamori S, et al. An essential role for vesicular glutamate transporter 1 (VGLUT1) in postnatal development and control of quantal size. Proc Natl Acad Sci USA. 2004;101:7158–7163.[Epub 2004 April 21]

PII: S0197-4580(06)00076-5

doi: 10.1016/j.neurobiolaging.2006.02.010

Neurobiology of Aging
Volume 28, Issue 4 , Pages 568-578 , April 2007

Article Tools

* Image Usage & Resolution